middle.news
Why Anatara’s GaRP Trial Missed Its Mark but Still Holds Promise
6:02pm on Wednesday 13th of August, 2025 AEST
•
Healthcare
Read Story
Why Anatara’s GaRP Trial Missed Its Mark but Still Holds Promise
6:02pm on Wednesday 13th of August, 2025 AEST
Key Points
35% increase in net loss to $1.95 million for FY25
GaRP Phase II IBS trial met safety but missed primary efficacy endpoint
Secondary endpoints showed significant anxiety reduction and symptom relief
New anti-obesity pre-clinical project initiated
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anatara Lifesciences (ASX:ANR)
OPEN ARTICLE